<DOC>
	<DOCNO>NCT01577316</DOCNO>
	<brief_summary>The hypothesis propose study 2011-2012 Seasonal Influenza Vaccine ( include H3N2 H1N1 subtypes serotype A strain serotype B ) administer 15ug ( without adjuvant ) via intramuscular pregnant woman safe immunogenic .</brief_summary>
	<brief_title>Evaluate Immunogenicity Safety 2011-2012 Vaccine Against Seasonal Influenza Pregnant Women</brief_title>
	<detailed_description>Despite fact influenza vaccination pregnant woman amply recommend , coverage influenza vaccination low . In general , study safety vaccine group , particularly first three month pregnancy evaluate trivalent vaccine contain inactivate pandemic 2009 H1N1 virus . Studies controversial regard passage maternal antibody protection newborn . The investigator propose evaluate safety immunogenicity 2011-2012 seasonal trivalent influenza vaccine ( Northern hemisphere ) ( contain A/California/7/2009 ( H1N1 ) -like virus ; A/Perth/16/2009 ( H3N2 ) -like virus ; B/Brisbane/60/2008-like virus ) produce Sanofi Pasteur . Study design Phase II/III , two arm , non-randomized clinical trial . The investigator recruit 120 pregnant woman , 18 39 year age , 14 34 week pregnant 120 non-pregnant woman . Trivalent influenza vaccine ( 0.5ml ) administer IM deltoid zone . Participants observe 30 min post-vaccination acute adverse reaction periodically 60 day post-vaccination reactogenicity , adverse effect severe adverse effect . Baseline 28 day influenza antibody measure hemagglutination microneutralization . Umbilical cord blood ( 10ml ) drawn delivery . Newborns follow monthly growth morbidity six month age . If necessary , referred appropriate clinical care . Main outcome seroconversion seroresponse 28 day post vaccination . Results adjust study group relevant covariables.Safety analyze accord type , severity study group .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>I.Selection Criteria pregnant woman I.a.Inclusion Criteria 1 . Pregnant woman age 18 39 year 2 . Have make least one prenatal visit confirm pregnancy 3 . Available followup time 4 . To 14 34 week gestation 5 . If recruitment conduct August November 2011 , patient could 6 . Received Seasonal Influence Vaccine previous period , H1N1 vaccine 7 . Agree participate study provide inform consent 8 . Good health accord clinical evaluation participant , confirm : heart 9 . Rate le 100 ' , systolic blood pressure le 140 mm Hg , diastolic less 10 . Equal 90 mmHg , oral temperature less equal 37.4° C 11 . Normal physical exam laboratory test within 28 day prior recruitment 12 . HIVnegative test I. b.Exclusion criterion 1 . Preeclampsia eclampsia 2 . Treatment immunosuppressive drug 3 . Receipt blood product , 120 day prior HIV screen 4 . Receipt immunoglobulin 60 day prior screen HIV 5 . Have receive live attenuate vaccine 30 day prior vaccination 6 . Have receive inactivated vaccine within 14 day prior vaccination 7 . Treatment latent active tuberculosis 8 . Autoimmune disease immunodeficiency 9 . Contraindication receive seasonal influenza vaccine 10 . Vaccine side effect 11 . History angioedema . 12 . Unstable asthma 13 . Diabetes 14 . Thyroidectomy thyroid disease last 12 month 15 . Idiopathic urticaria 16 . Hypertension wellcontrolled treatment 17 . Medically diagnosed bleeding diathesis , coagulopathy platelet disorder 18 . Active malignant tumor noteffective treatment 19 . Asplenia 20 . Allergic reaction antibiotic 21 . Guillain Barre 22 . Psychiatric condition difficult adherence protocol II.Selection criterion nonpregnant woman II . a.Inclusion criterion Nonpregnant woman age 18 39 year Negative pregnancy test 24 hour prior administration vaccine Agree participate study provide informed consent Good health accord clinical evaluation participant , confirm : heart rate le 100 ' , systolic blood pressure le 140 mmHg , diastolic less equal 90 mmHg , oral temperature less equal 37.4°C Normal physical exam laboratory test within 28 day prior recruitment HIVnegative test Agree get pregnant study follow effective contraceptive method Good health , determine history Receive seasonal influenza vaccine least two week prior inclusion study II . b.Exclusion criterion Being treatment immunosuppressive drug Receipt blood product , 120 day prior HIV screen Receipt immunoglobulin 60 day prior screen HIV Have receive live attenuate vaccine 30 day vaccination Have receive inactivated vaccine within 14 day prior vaccination Treatment latent active tuberculosis Autoimmune disease immunodeficiency Contraindication receive seasonal influenza vaccine Vaccine side effect History angioedema Unstable asthma Diabetes Type 2 Thyroidectomy thyroid disease require treatment past 12 month . Idiopathic urticaria Hypertension wellcontrolled treatment Medically diagnose bleed diathesis , coagulopathy platelet disorder Active malignant tumor Convulsive condition Anatomic functional asplenia Allergic reaction antibiotic Guillain Barre Psychiatric condition</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>39 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>vaccination</keyword>
	<keyword>Influenza</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>Safety</keyword>
</DOC>